News stories about Selecta Biosciences (NASDAQ:SELB) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Selecta Biosciences earned a news impact score of 0.20 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.5378972584345 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Selecta Biosciences (NASDAQ:SELB) traded up $0.10 during trading on Monday, reaching $11.03. The company had a trading volume of 160,700 shares, compared to its average volume of 188,175. The stock has a market cap of $246.37, a PE ratio of -3.56 and a beta of -7.16. Selecta Biosciences has a 1 year low of $8.70 and a 1 year high of $24.02. The company has a current ratio of 9.48, a quick ratio of 9.48 and a debt-to-equity ratio of 0.32.

A number of analysts recently commented on the company. Canaccord Genuity reiterated a “buy” rating on shares of Selecta Biosciences in a research report on Wednesday, January 3rd. UBS Group cut Selecta Biosciences from a “buy” rating to a “neutral” rating in a research report on Thursday, November 9th. Zacks Investment Research upgraded Selecta Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 12th. Finally, ValuEngine cut Selecta Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Selecta Biosciences has an average rating of “Hold” and an average target price of $23.50.

In other Selecta Biosciences news, Director Timothy A. Springer purchased 57,598 shares of the stock in a transaction on Tuesday, November 14th. The stock was bought at an average price of $9.27 per share, for a total transaction of $533,933.46. Following the acquisition, the director now directly owns 461,349 shares of the company’s stock, valued at $4,276,705.23. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Earl Sands purchased 7,500 shares of the stock in a transaction on Friday, November 17th. The stock was acquired at an average price of $10.26 per share, with a total value of $76,950.00. Following the acquisition, the insider now directly owns 7,500 shares in the company, valued at $76,950. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 90,098 shares of company stock valued at $843,933. 41.90% of the stock is currently owned by company insiders.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/selecta-biosciences-selb-getting-somewhat-favorable-news-coverage-analysis-finds/1798592.html.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Insider Buying and Selling by Quarter for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with Analyst Ratings Network's FREE daily email newsletter.